These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37393791)

  • 21. Novel inhibitors of HIV-1 integration.
    Witvrouw M; Van Maele B; Vercammen J; Hantson A; Engelborghs Y; De Clercq E; Pannecouque C; Debyser Z
    Curr Drug Metab; 2004 Aug; 5(4):291-304. PubMed ID: 15320701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus: The potential of medicinal plants as antiretroviral therapy.
    Shahzad M; Chen H; Akhtar T; Rafi A; Zafar MS; Zheng YT
    J Med Virol; 2022 Jun; 94(6):2669-2674. PubMed ID: 35128696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
    De Clercq E
    Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and future antiretroviral treatment options in paediatric HIV infection.
    Giaquinto C; Morelli E; Fregonese F; Rampon O; Penazzato M; de Rossi A; D'Elia R
    Clin Drug Investig; 2008; 28(6):375-97. PubMed ID: 18479179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 35-Year Review of Pre-Clinical HIV Therapeutics Research Reported by NIH ChemDB: Influences of Target Discoveries, Drug Approvals and Research Funding.
    Jackson SS; Sumner LE; Finnegan MA; Billings EA; Huffman DL; Rush MA
    J AIDS Clin Res; 2020; 11(11):. PubMed ID: 33364074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational drugs with dual activity against HBV and HIV (Review).
    Sun S; Yang Q; Sheng Y; Fu Y; Sun C; Deng C
    Exp Ther Med; 2021 Jan; 21(1):35. PubMed ID: 33262821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus.
    Hartman TL; Yang L; Helfrick AN; Hassink M; Shank NI; George Rosenker K; Scerba MT; Saha M; Hughes E; Wang AQ; Xu X; Gupta P; Buckheit RW; Appella DH
    Antiviral Res; 2016 Oct; 134():216-225. PubMed ID: 27568924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assault on resistance: the use of computational chemistry in the development of anti-HIV drugs.
    Smith MB; Smith RH; Jorgensen WL
    Curr Pharm Des; 2006; 12(15):1843-56. PubMed ID: 16724951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery.
    Richardson P
    Expert Opin Drug Discov; 2021 Nov; 16(11):1261-1286. PubMed ID: 34074189
    [No Abstract]   [Full Text] [Related]  

  • 32. Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview.
    Kurapati KR; Atluri VS; Samikkannu T; Garcia G; Nair MP
    Front Microbiol; 2015; 6():1444. PubMed ID: 26793166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (
    Zhang J; Vernon K; Li Q; Benko Z; Amoroso A; Nasr M; Zhao RY
    Pathogens; 2021 Jun; 10(7):. PubMed ID: 34202872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Two-Drug Regimens That Are Approved from 2018 to 2022 for the Treatment of Human Immunodeficiency Virus (HIV) Disease and Its Opportunistic Infections.
    Sivanandy P; Ng Yujie J; Chandirasekaran K; Hong Seng O; Azhari Wasi NA
    Microorganisms; 2023 May; 11(6):. PubMed ID: 37374953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.
    Sanusi ZK; Govender T; Maguire GEM; Maseko SB; Lin J; Kruger HG; Honarparvar B
    J Comput Aided Mol Des; 2018 Mar; 32(3):459-471. PubMed ID: 29397520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
    Voshavar C
    Curr Top Med Chem; 2019; 19(18):1571-1598. PubMed ID: 31237209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome.
    Balint GA
    Pharmacol Ther; 2001 Jan; 89(1):17-27. PubMed ID: 11316511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The chemical bases of the various AIDS epidemics: recreational drugs, anti-viral chemotherapy and malnutrition.
    Duesberg P; Koehnlein C; Rasnick D
    J Biosci; 2003 Jun; 28(4):383-412. PubMed ID: 12799487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The AIDS dilemma: drug diseases blamed on a passenger virus.
    Duesberg P; Rasnick D
    Genetica; 1998; 104(2):85-132. PubMed ID: 10220905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitroimidazoles, Quinolones and Oxazolidinones as Fluorine Bearing Antitubercular Clinical Candidates.
    Patel RV; Keum YS; Park SW
    Mini Rev Med Chem; 2015; 15(14):1174-86. PubMed ID: 26156417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.